Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;30(7):373-380.
doi: 10.1097/JXX.0000000000000076.

Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice

Courtney S Davis  1 , Joshua W Fleming, Scott S Malinowski, Meagan A Brown, Laurie W Fleming
Affiliations
Review

Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice

Courtney S Davis et al. J Am Assoc Nurse Pract. 2018 Jul.

Abstract

Background and purpose: In the past decade, there has been much advancement in oral antidiabetic agents, but few changes in insulin therapy. With the addition of the ultra-long-acting insulins, insulin glargine U300 (IGlar 300) and insulin degludec (IDeg 100 and IDeg 200), it is important to understand key aspects in the agents' clinical properties, efficacy, safety, dosing, packaging, and place in therapy.

Methods: A literature review was conducted using PubMed database and was limited to English, full-text articles published from January 2000 to January 2018. The following search terms were used: insulin glargine 300, insulin degludec, Toujeo, Tresiba, and ultra-long-acting insulin.

Conclusions: These agents are longer acting with sustained insulin coverage as compared with other basal insulins while having a low potential for hypoglycemia. Efficacy and safety profiles are quite good, and potential for weight gain was similar to IGlar 100.

Implications for practice: Depending on the patient's needs, these newer agents may offer some advantages. Insulin glargine U300 and IDeg 200 are concentrated, allowing for administration of large doses by less volume, thereby theoretically improving absorption. For patients needing flexible dosing, IDeg may be beneficial. The ultra-long-acting agents may also be useful if it is suspected that the basal insulin is not lasting the entire day.

PubMed Disclaimer

References

    1. American Diabetes Association. (2018). Standards of medical care in diabetes—2018 abridged for primary Care providers. Clinical Diabetes, 36, 14–37.
    1. Ashwell S. G., Gebbie J., Home P. D. (2006). Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine, 23, 879–886.
    1. Becker R. H. A., Dahmen R., Bergmann K., Lehmann A., Jax T., Heise T. (2015). New insulin glargine 300 Units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL. Diabetes Care, 38, 637–643.
    1. Bergenstal R. M., Bailey T. S., Rodbard D., Ziemen M., Guo H., Muehlen-Bartmer I., Ahmann A.J. (2017). Comparison of insulin glargine 300 Units/mL and 100 Units/mL in adults with type 1 Diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care, 40, 554–560.
    1. Bode B. W., Buse J. B., Fisher M., Garg S. K., Marre M., Merker L., Heller S. R. (2013). Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN ® basal-bolus type 1): 2-year results of a randomized clinical trial. Diabetic Medicine, 30, 1293–1297.

MeSH terms

LinkOut - more resources